Kepos Capital’s Myriad Genetics MYGN Stock Holding History

Kepos Capital’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-21,885	Closed	-$596K	–	263
2019 Q4	$596K	Sell	21,885 -13,682	-38%	-$376K	0.06%	208
2019 Q3	$1.02M	Sell	35,567 -32,756	-48%	-$954K	0.1%	100
2019 Q2	$1.9M	Sell	68,323 -1	-0%	-$28	0.19%	115
2019 Q1	$2.27M	Sell	68,324 -25,178	-27%	-$766K	0.17%	155
2018 Q4	$2.72M	Buy	93,502 +16,442	+21%	+$591K	0.21%	128
2018 Q3	$3.54M	Buy	+77,060	New	+$3.43M	0.18%	119

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Kepos Capital's MYGN Position: Q1 2020 in Review

Kepos Capital sold out of Myriad Genetics (MYGN) in Q1 2020, closing a stake of 21,885 shares — an estimated $596K sold.

Kepos Capital first reported a position in MYGN in Q3 2018 and held it in 6 quarters. The position peaked at $3.54M in Q3 2018. 190 funds tracked by Wall St. Rank hold MYGN as of Q1 2020.

Kepos Capital reported no remaining Myriad Genetics position as of Q1 2020 after selling out during the quarter.
Kepos Capital sold 21,885 Myriad Genetics shares in Q1 2020, an estimated $596K.
Kepos Capital first reported a position in Myriad Genetics in Q3 2018 and held it in 6 quarters.
Kepos Capital's Myriad Genetics position peaked at $3.54M in Q3 2018.
190 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2020.

Based on Kepos Capital's 13F filing for Q1 2020, filed 12 May 2020.